Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCAPOX for GI Malignancies
NCT06648785Phase 2Enrolling by invitation
- Sponsor
- University of Vermont Medical Center
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in gastrointestinal malignancy, sponsored by University of Vermont Medical Center. Started Oct 2024; status: enrolling by invitation.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastrointestinal malignancy
Beyond the preview
Go deeper on NCT06648785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648785.